Photocure ASA (PHCUF)
PHCUF Stock Price Chart
Explore Photocure ASA interactive price chart. Choose custom timeframes to analyze PHCUF price movements and trends.
PHCUF Company Profile
Discover essential business fundamentals and corporate details for Photocure ASA (PHCUF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
24 Sept 2013
Employees
99.00
Website
https://www.photocure.comCEO
Daniel Schneider
Description
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
PHCUF Financial Timeline
Browse a chronological timeline of Photocure ASA corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 29 Oct 2025
Revenue estimate is $130.00M.
Earnings released on 30 Jul 2025
EPS came in at $0.18 surpassing the estimated -$0.00 by +6.97K%, while revenue for the quarter reached $135.62M , beating expectations by +940.08%.
Earnings released on 8 May 2025
EPS came in at -$0.09 falling short of the estimated -$0.00 by -2.08K%, while revenue for the quarter reached $125.34M , missing expectations by -3.96%.
Earnings released on 19 Feb 2025
EPS came in at -$0.21 falling short of the estimated $0.02 by -1.24K%, while revenue for the quarter reached $141.68M , beating expectations by +4.95%.
Earnings released on 13 Nov 2024
EPS came in at -$0.13 falling short of the estimated -$0.02 by -461.80%, while revenue for the quarter reached $120.23M , beating expectations by +982.21%.
Earnings released on 7 Aug 2024
EPS came in at $0.04 , while revenue for the quarter reached $13.61M .
Earnings released on 15 May 2024
EPS came in at -$0.03 , while revenue for the quarter reached $10.91M .
Earnings released on 21 Feb 2024
EPS came in at $0.05 , while revenue for the quarter reached $13.99M .
Earnings released on 30 Sept 2023
EPS came in at -$0.02 , while revenue for the quarter reached $10.05M .
Earnings released on 30 Jun 2023
EPS came in at $0.01 , while revenue for the quarter reached $13.43M .
Earnings released on 31 Mar 2023
EPS came in at -$0.04 , while revenue for the quarter reached $10.14M .
Earnings released on 23 Feb 2023
EPS came in at -$0.79 falling short of the estimated -$0.23 by -243.48%, while revenue for the quarter reached $10.62M .
Earnings released on 2 Nov 2022
EPS came in at -$0.37 falling short of the estimated -$0.16 by -131.25%, while revenue for the quarter reached $9.81M .
Earnings released on 10 Aug 2022
EPS came in at -$0.68 falling short of the estimated -$0.34 by -100.00%, while revenue for the quarter reached $10.14M .
Earnings released on 11 May 2022
EPS came in at -$0.82 falling short of the estimated -$0.48 by -70.83%, while revenue for the quarter reached $9.26M .
Earnings released on 23 Feb 2022
EPS came in at -$1.05 , while revenue for the quarter reached $10.71M .
Earnings released on 17 Nov 2021
EPS came in at -$0.10 falling short of the estimated -$0.04 by -150.00%, while revenue for the quarter reached $9.98M .
Earnings released on 11 Aug 2021
EPS came in at -$0.40 , while revenue for the quarter reached $10.51M .
Earnings released on 19 May 2021
EPS came in at $0.57 surpassing the estimated -$0.26 by +319.23%, while revenue for the quarter reached $10.33M .
Earnings released on 3 Mar 2021
EPS came in at $0.38 , while revenue for the quarter reached $97.90M .
Earnings released on 10 Nov 2020
EPS came in at $0.04 surpassing the estimated -$0.78 by +105.13%, while revenue for the quarter reached $49.94M .
PHCUF Stock Performance
Access detailed PHCUF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.